BIO.News Newsletter

Biopharma can't comply with tariffs without guidance. Plus, BIO's message on AMR. (779 words, 3 minutes, 7 seconds)

Women's biotech ecosystem grows. Plus, patient perspectives on access matter. (1,012 words, 4 minutes, 3 seconds)

A roundup of state-level actions impacting biotech. And a reminder: Most support vaccination. (712 words, 2 minutes, 51 seconds)

A flurry of congressional activity brings hope of 340B reform. Meanwhile, BIO comments on clinical trial reform. (665 words, 2 minutes, 40 seconds)

ICYMI: The PASTEUR Act was reintroduced in the Senate. Plus, more from BIO 2026, including the latest on the 340B program and what the media was covering at the Convention. (639 words, 3 minutes, 12 seconds)

As BIO 2026 comes to a close, we look ahead to biotech's sixth decade. Pioneering patients remind us why innovation matters, and experts outline what will shape biotech's next decade, and leaders warn that protecting intellectual property remains essential to American biotech leadership. (882 words, 4 minutes, 25 seconds)

Day 3 of BIO 2026 looked ahead to biotech's next chapter: how AI could accelerate drug discovery, why U.S. biotechnology leadership is a national security priority, and what states can do to compete for the industry's next generation of growth. (670 words, 3 minutes, 14 seconds)

On Tuesday, BIO 2026 attendees explored what it will take to maintain America's innovation edge, while a new industry report offered fresh evidence that capital is returning to the sector and emerging biotechs remain the industry's innovation engine. Plus, leadership advice from Gary Sinise and Marcus Freeman. (675 words, 3 minutes, 15 seconds)

Patient groups happy Virginia won't have a PDAB. Plus, seeking clarity about onshoring agreements. (789 words, 3 minutes, 10 seconds)

Hearings on data protection and IP have big significance for biotech. (884 words, 3 minutes, 33 seconds)